Rianne Biemans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rianne Biemans has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Ludwig Jerome Dubois
The M-Lab, Department of Precision Medicine, GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands
3 shared publications Philippe Lambin
Dept. of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, the Netherlands
3 shared publications- Ala Yaromina
The M-Lab, Department of Precision Medicine, GROW—School for Oncology and Reproduction, Maastricht University, 6229 ER Maastricht, The Netherlands
2 shared publications - Natasja Lieuwes
GROW - School for Oncology & Developmental Biology, Maastricht University, the Netherlands; MAASTRO Lab, Maastricht University Medical Centre, the Netherlands
2 shared publications - Wouter van Elmpt
Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands
2 shared publications Ala Yaromina
Department of Radiation Oncology (MAASTRO), Division of Hematology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 September 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 124 (3) , 513-520
A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the “Low Drug Uptake Volume”
- 1 September 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 124 (3) , 513-520
Open AccessA novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the “Low Drug Uptake Volume”
- Open Access
- 1 April 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119, S179
OC-0382: A novel concept to tumour targeting: inverse dose-painting or targeting the "Low uptake drug volume"
- 1 April 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119, S179
Open AccessOC-0382: A novel concept to tumour targeting: inverse dose-painting or targeting the "Low uptake drug volume"
- Open Access
- 1 September 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 116 (3) , 438-442
Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model
- 1 September 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 116 (3) , 438-442
Open AccessCombination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model
- Open Access
- 23 July 2015
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 91 (10) , 778-785
High dose rate and flattening filter free irradiation can be safely implemented in clinical practice
Purpose: We hypothesize that flattening filter free (FFF) high dose rate irradiation will decrease cell survival in normal and cancer cells with more pronounced effects in DNA repair deficient cells. Additionally, we hypothesize that removal of the flattening filter will result in an enhanced relative biological effectiveness independent of the dose rate. Materials and methods: Clonogenic survival was assessed after exposure to dose rates of 4 or 24 Gy/min (FFF 10 megavolt [MV] photon beam) using a Varian TrueBeam accelerator. Additionally, cells were exposed to 4 Gy/min with or without flattening filter. Relative biological effectiveness estimations were performed comparing the different beam photon spectra. Results: Cell survival in tumor and normal cell lines was not influenced by high dose rate irradiation. The intrinsic radiation sensitivity of DNA repair deficient cells was not affected by high dose rate compared to normal dose rate. Furthermore, the relative biological effectiveness was not significantly different from unity in any of the cell lines for both FFF and conventional flattened beam exposures. Conclusions: High dose rate irradiation did not affect long-term survival and DNA repair for cell lines of different tissues. This suggests that high dose rate does not influence treatment outcome or treatment toxicity and could be safely implemented in clinical routine.
- 23 July 2015
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 91 (10) , 778-785
Open AccessHigh dose rate and flattening filter free irradiation can be safely implemented in clinical practice
Purpose: We hypothesize that flattening filter free (FFF) high dose rate irradiation will decrease cell survival in normal and cancer cells with more pronounced effects in DNA repair deficient cells. Additionally, we hypothesize that removal of the flattening filter will result in an enhanced relative biological effectiveness independent of the dose rate. Materials and methods: Clonogenic survival was assessed after exposure to dose rates of 4 or 24 Gy/min (FFF 10 megavolt [MV] photon beam) using a Varian TrueBeam accelerator. Additionally, cells were exposed to 4 Gy/min with or without flattening filter. Relative biological effectiveness estimations were performed comparing the different beam photon spectra. Results: Cell survival in tumor and normal cell lines was not influenced by high dose rate irradiation. The intrinsic radiation sensitivity of DNA repair deficient cells was not affected by high dose rate compared to normal dose rate. Furthermore, the relative biological effectiveness was not significantly different from unity in any of the cell lines for both FFF and conventional flattened beam exposures. Conclusions: High dose rate irradiation did not affect long-term survival and DNA repair for cell lines of different tissues. This suggests that high dose rate does not influence treatment outcome or treatment toxicity and could be safely implemented in clinical routine.